Post-operative Radiotherapy in Poor Responders Ewing's Sarcoma Patients

Status Withdrawn

Clinical Trial Summary

Local recurrence after surgical resection is a complex phenomenon. An important predictive factor is the response to chemotherapy. Central site of disease may be a second independent predictive factor (Lin et al. 2007). Patients with more than 10% viable tumour cells at surgery following neo-adjuvant chemotherapy had a less favourable outcome with an Event-free Survival [EFS] of 47% after 10 years. Patients with good histological response (< 10% viable tumour cells) after chemotherapy alone had a prognosis of about 70% after 10 years.

However, further studies are necessary to determine the merit of adjuvant radiation for high-risk patients (poor responders). Taking into consideration that the toxicity and morbidity of combined surgery and radiation is greater than either alone and must be closely monitored.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01734863
Study type	Interventional
Source	Children's Cancer Hospital Egypt 57357
Contact
Status	Withdrawn
Phase	Phase 3
Start date	September 2012
Completion date	December 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01674101` - Effects of Preoperative Physical Therapy in Patients With Lower Extremity Malignancy	N/A
Completed	`NCT02736565` - Pbi-shRNA™ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma	Phase 1
Completed	`NCT00563680` - QUILT-3.025: A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell Tumors	Phase 2
Completed	`NCT00987636` - Study in Localized and Disseminated Ewing Sarcoma	Phase 3
Terminated	`NCT00038142` - Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) in High Risk Ewing's Sarcoma Patients	Phase 2
Completed	`NCT02890758` - Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803	Phase 1
Completed	`NCT01583543` - Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma	Phase 2
Terminated	`NCT01313884` - Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma	Phase 2
Completed	`NCT01696669` - Study of Intensive Chemotherapy, Surgery and Radiotherapy to Treat Ewing's Sarcoma in Children and Young Adults	Phase 2
Completed	`NCT00004853` - Comparison of Filgrastim and Filgrastim SD/01in Boosting White Cell Counts After Intensive Chemotherapy	Phase 1
Terminated	`NCT00568464` - Study on VCD/IE in the Patients With Ewing's Sarcoma Family of Tumors (ESFT)	Phase 2
Completed	`NCT00001686` - Evaluation, Treatment, and Natural History of Children and Young Adults With Cancer or Rare Diseases
Completed	`NCT00492141` - Aerosol L9-NC and Temozolomide in Ewing's Sarcoma	Phase 1/Phase 2
Active, not recruiting	`NCT00541411` - Phase II Pilot Study of Vincristine, Adriamycin, Actinomycin D, Ifosfamide Combination Chemotherapy in Ewing's Sarcoma	N/A
Completed	`NCT02063022` - Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma	Phase 3
Completed	`NCT01598454` - Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides	Phase 1
Recruiting	`NCT03442465` - Assessment of Healing and Function After Reconstruction Surgery for Bone Sarcomas
Completed	`NCT02511132` - A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma	Phase 2
Completed	`NCT00923650` - Informed Consent in Pediatric Cancer Trials	N/A
Completed	`NCT01962103` - Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors	Phase 1/Phase 2